- Home
- LLAP vs RFL Comparison
LLAP vs RFL Comparison
Compare LLAP & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLAP
- RFL
- Stock Information
- Founded
- LLAP 2013
- RFL 2017
- Country
- LLAP United States
- RFL United States
- Employees
- LLAP N/A
- RFL N/A
- Industry
- LLAP Military/Government/Technical
- RFL Real Estate
- Sector
- LLAP Industrials
- RFL Finance
- Exchange
- LLAP Nasdaq
- RFL Nasdaq
- Market Cap
- LLAP 50.3M
- RFL 48.4M
- IPO Year
- LLAP N/A
- RFL N/A
- Fundamental
- Price
- LLAP $0.25
- RFL $2.00
- Analyst Decision
- LLAP Buy
- RFL
- Analyst Count
- LLAP 3
- RFL 0
- Target Price
- LLAP $2.58
- RFL N/A
- AVG Volume (30 Days)
- LLAP 5.4M
- RFL 47.2K
- Earning Date
- LLAP 11-12-2024
- RFL 10-28-2024
- Dividend Yield
- LLAP N/A
- RFL N/A
- EPS Growth
- LLAP N/A
- RFL N/A
- EPS
- LLAP N/A
- RFL N/A
- Revenue
- LLAP $133,107,000.00
- RFL $540,000.00
- Revenue This Year
- LLAP $8.71
- RFL N/A
- Revenue Next Year
- LLAP $34.59
- RFL N/A
- P/E Ratio
- LLAP N/A
- RFL N/A
- Revenue Growth
- LLAP 10.75
- RFL 92.86
- 52 Week Low
- LLAP $0.23
- RFL $1.29
- 52 Week High
- LLAP $1.62
- RFL $2.14
- Technical
- Relative Strength Index (RSI)
- LLAP 35.74
- RFL 74.68
- Support Level
- LLAP $0.25
- RFL $1.65
- Resistance Level
- LLAP $0.27
- RFL $1.94
- Average True Range (ATR)
- LLAP 0.01
- RFL 0.10
- MACD
- LLAP 0.01
- RFL 0.02
- Stochastic Oscillator
- LLAP 26.43
- RFL 100.00
About LLAP Terran Orbital Corporation
Terran Orbital Corp is a manufacturer of satellite products primarily serving the aerospace and defense industries. The company provide end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of our military, civil, and commercial customers. Geographically company operates in United States and Europe. Majority of the revenue is generated from United States.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.